Cannabigerol (CBG) is one of over 120 cannabinoids found in the cannabis plant. CBG is non-psychoactive, and is a minor component of cannabis, with the majority of CBG actually converting into other cannabinoids during plant growth. Most of the CBG turns into THC and CBD, with usually less than 1% of CBG remaining. Initial studies are showing potential for CBG’s medicinal use, and breeders are experimenting to obtain a higher CBG content in cannabis. The low levels of CBG in the end products have resulted in scientists manipulating the plant genetics in an attempt to produce higher concentrations of CBG. A Dutch company called Bedrocan BV Medicinal Cannabis has been producing a CBG specific strain called Bediol since 2007 for its anti-inflammatory effects.
The Physiological Systems in which CBG impacts appear to be very specific. There are currently seven listed medical issues where CBG has shown potential for assisting. Notably, some testing is showing evidence in CBG’s effective treatment of glaucoma, by reducing intraocular pressure, as well as treating inflammatory bowel disease in mice. CBG has even shown promise in blocking receptors that cause cancer cell growth, and as such, could one day be used to fight cancer. In 2017 the University of Naples released a study showcasing the ability for CBG to work as appetite stimulants. Although this study was done on rats, it still has potential as non-psychotropic therapy for those who suffer from appetite loss-related ailments.
Although the research is still very new, scientists are excited about the initial results of CBG, as well as CBG in conjunction with other cannabinoids in treating a wide range of health problems. With every succeeding strain generation, the genetic profiles required for greater CBG yields are approaching a point to effectively produce medicinal benefits on their own.
 NCBI Article 1
 NCBI Article 2
 NCBI Article 3
 NCBI Article 4
 NCBI Article 5
 Leafly Article